Propel mometasone furoate implant
From LIMSWiki
Jump to navigationJump to searchThe printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Steroid-eluting sinus stents may be used in addition to endoscopic sinus surgery. They are, however, of unclear benefit as of 2015.[1]
One version releases mometasone furoate. It is a bioabsorbable steroid-eluting stent. It delivers steroids over a 30-day period prior to dissolving.[2]
Society and culture
A number of brands exist including Relieva Stratus Spacer and Propel sinus implant.[3][4]
Approval
One brand received pre-market approval from the FDA in 2011.
See also
References
- ^ Huang, Z; Hwang, P; Sun, Y; Zhou, B (10 June 2015). "Steroid-eluting sinus stents for improving symptoms in chronic rhinosinusitis patients undergoing functional endoscopic sinus surgery". The Cochrane Database of Systematic Reviews (6): CD010436. doi:10.1002/14651858.CD010436.pub2. PMID 26068957.
- ^ Lee, Jivianne T; Han, Joseph K (2013). "Sinus implants for chronic rhinosinusitis: Technology evaluation". Expert Opinion on Drug Delivery. 10 (12): 1735–48. doi:10.1517/17425247.2013.839654. PMID 24088141. S2CID 22761647.
- ^ Liang, Jonathan; Lane, Andrew P. (2012). "Topical Drug Delivery for Chronic Rhinosinusitis". Current Otorhinolaryngology Reports. 1 (1): 51–60. doi:10.1007/s40136-012-0003-4. PMC 3603706. PMID 23525506.
- ^ Kennedy, David W (2012). "The PROPEL™ steroid-releasing bioabsorbable implant to improve outcomes of sinus surgery". Expert Review of Respiratory Medicine. 6 (5): 493–8. doi:10.1586/ers.12.53. PMID 23134241. S2CID 207223274.
Notes
This article is a direct transclusion of the Wikipedia article and therefore may not meet the same editing standards as LIMSwiki.
